

There is free confidential help on campus for students with psychological disabilities (Bipolar, Depression, Anxiety, etc.). Please contact Kim A. Warren, MSW, PhD, LCSW, Supported Education Advisor, at 4825252 or at kimawarren@louisiana.edu located in the Conference Center, Room 126. You can also visit the SSD website for information on SSD and SEP services including eligibility requirements.

COURSE TITLE: CODI612-1SP08
ID = 205827 & PW = dAZdERc0

updated January 18, 2008

INSTRUCTOR: John Oller, Ph.D., Hawthorne Regents Professor, 337-962-4649
joller@louisiana.edu GA, Evra Günhan gunhan@louisiana.edu
Office Foster 203: Hours TR 1:00-4:00 by appointment.

CLASS TIME: W 1:00 PM - 3:30 PM Foster 203

TEXTS: Jepson, B., & Johnson, J. (2007). *Changing the course of autism: A scientific approach for parents and physicians*. Boulder, CO: Sentient Publications.

McCarthy, J. (2007). *Louder than words: A mother's journey in healing autism*. New York: Dutton.

Oller, J. W., Jr. & Rascón, D. (1999). Applying sign theory to autism. *Clinical Linguistics and Phonetics*, 13(2), 77-112.

This course is about the causes of autism spectrum disorders and their diagnosis. The main requirements consist of readings, seminar type class discussions, and a research paper/progress report. Please read the assigned material before each class meeting and come prepared to talk about it in class. This course is concerned mainly with what causes autism spectrum disorders (ASDs). We are also concerned with diagnosis and assessment of treatment protocols. What indicators are the best predictors of observed behavioral improvements where they occur?

CODI 612-1SP08: Tentative Calendar

#	D	Date	SUBJECT -MATTER *WRITING DUE	READ FOR NEXT
<i>Monday, January 21, 2008 Martin Luther King Day</i>				
1	W	1/23	Syllabus.	J&J xiii-7 & McCarthy
2	W	1/30	Discuss ASDs from the parent's perspective. <i>What should be the objective of SLPs, clinicians, doctors & researchers re ASDs?</i>	J&J Ch 1-4 pp. 8-41
		2/4-6	Mardi Gras Holidays	J&J Ch 5-7 pp. 42-64
3	W	2/8	What is autism? Disease & auto-immunity.	J&J Ch 8-9 pp. 65-99
4	W	2/15	MMR & the gut.	J&J Ch 10-11 pp. 100-139
5	W	2/22	Detoxification & Hg.	J&J Ch 12 pp. 140-164
6	W	2/29	More on Hg. <i>Sum up some of the current research.</i>	J&J Ch 13-14 pp. 164-180; O&R 77-112
7	W	3/7	Figuring it out.	J&J Ch 15-17 pp. 181-219
8	W	3/14	Treating the gut. <i>View the Kurtz film about here.</i>	
9	W	3/21-30	Easter/Spring Break	J&J Ch 18-21 pp. 220-260

#	D	Date	SUBJECT -MATTER *WRITING DUE	READ FOR NEXT
10	W	4/4	Detox, immunity, & the brain.	Selected articles.
11	W	4/11	Participant led discussion 1.	Selected articles.
12	W	4/18	Participant led discussion 2.	Selected articles.
13	W	4/25	Participant led discussion 3.	Selected articles.
14	W	5/2	Participant led discussion 4.	Selected articles.
15	W	5/8	Participant led discussion 5. *Term paper due. (Last class meeting.)	

Possible Additional Readings & References

Aposhian, H. V., Bruce, D. C., Alter, W., Dart, R. C., Hurlbut, K. M., Aposhian, M. M. (1992). Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid - correlation with Dental Amalgam Score. *FASEB Journal*, 6 (7), 2472-2476.

Barlow, B. K., Cory-Slechta, D. A., Richfield, E. K., & Thiruchelvam, M. (2007). The gestational environment and Parkinson's disease: Evidence for neurodevelopmental origins of a neurodegenerative disorder. *Reproductive Toxicology*, 23(3), 457-470.

Barr, L. (2004). EPA's draft use reduction program. Retrieved December 27, 2007, from <http://www.epa.gov/region5/air/mercury/meetings/Nov04/barr.pdf>

Bernard, S., Enayati, A., Redwood, L., Roger, H., and Binstock, T. (2001). Autism: a novel form of mercury poisoning. *Medical Hypotheses*, 56, 462-471.

Bernard, S., Enayati, A., Roger, H., Binstock, T., & Redwood, L. (2002). The role of mercury in the pathogenesis of autism. *Molecular Psychiatry*, 7, S42-S43, Suppl. 2.

Bernard, S., Redwood, L., & Blaxill, M. (2004). Thimerosal, mercury, and autism: Case study in the failure of the risk assessment paradigm. *Neurotoxicology*, 25(4), 710-710.

Bocca, B., Alimonti, A., Bomboi, G., Giubilei, F., & Forte, G. (2006). Alterations in the level of trace metals in Alzheimer's disease. *Trace Elements and Electrolytes*, 23(4), 270-276.

Burbacher, T. M., Shen, D. D., Liberato, N., Grant, K. S., Cernichiari, E., & Clarkson, T. (2005). Comparison of blood and brain mercury levels in infant monkeys exposed to methyl mercury or vaccines containing thimerosal. *Environmental Health Perspectives*, 113(8), 1015-1021.

Carvey, P. M., Punati, A., Newman, M. B. (2006). Progressive dopamine neuron loss in Parkinson's disease: The multiple hit hypothesis. *Cell Transplantation*, 15(3), 239-250.

Cedrola, S., Guzzi, G., Ferrari, D., Gritti, A., Vescovi, A. L., Pendergrass, J. C., La Porta C. A. M. (2003, March). Inorganic mercury changes the fate of murine CNS stem cells. *FASEB Journal*, 17(3), 869.

Clarkson, T. W. & Magos, L. (2006). The toxicology of mercury and its chemical compounds. *Critical Reviews in Toxicology*, 36, 609-662.

Counter, S. A., Buchanan, L. H. (2004). Mercury exposure in children: A review. *Toxicology and Applied Pharmacology*, 198 (2), 209-230.

Cox, C., Marsh, D., Myers, G. & Clarkson, T. (1995). Analysis of data on delayed development

from the 1971-1972 outbreak of methyl mercury poisoning in Iraq: Assessment of influential points. *NeuroToxicology*, 16(4), 727-730.

Dantzig, P. I. (2006). Parkinson's disease, macular degeneration and cutaneous signs of mercury toxicity. *Journal of Occupational and Environmental Medicine*, 48(7), 656-656.

Day, J. J., Reed, M. N., & Newland, M. C. (2005). Neuromotor deficits and mercury concentrations in rats exposed to methyl mercury and fish oil. *Neurotoxicology and Teratology*, 27(4), 629-641.

Domingo J. L. (2006). Aluminum and other metals in Alzheimer's disease: A review of potential therapy with chelating agents. *Journal of Alzheimer's Disease*, 10(2-3), 331-341.

Ferreira, S. T., Vieira, M. N. N., & De Felice, F. G. (2007). Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. *IUBMB LIFE* 59(4-5), 332-345.

Franco, J. L., Teixeira, A., Meotti, F. C., Ribas, C. M., Stringari, J., Pomblum, S. C. G., Moro A. M., Bohrer, D., Bairros, A. V., Dafre, A. L., Santos, A. R. S., Farina, M. (2006). Cerebellar thiol status and motor deficit after lactational exposure to methyl mercury. *Environmental Research* 102(1), 22-28.

Geier, D. A. & Geier, M. R. (2006a). An assessment of downward trends in neurodevelopmental disorders in the United States following removal of thimerosal from childhood vaccines. *Medical Science Monitor*, 12(6), CR231-CR239.

Geier, D. A. & Geier, M. R. (2006b). A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. *Hormone Research*, 66(4), 182-188.

Geier, D. A. & Geier, M. R. (2006c). An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States. *Journal of Toxicology and Environmental Health-Part A — Current Issues*, 69(15), 1481-1495.

Geier, D. A. & Geier, M. R. (2007a). A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. *Journal of Toxicology and Environmental Health-part A — Current Issues*, 70 (20), 1723-1730.

Geier, D. A. & Geier, M. R. (2007b). A prospective study of thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders. *Journal of Maternal-Fetal & Neonatal Medicine*, 20 (5), 385-390.

George, G. N., Prince, R. C., Gailer, J., Buttigieg, G. A., Denton, M. B., Harris, H. H., & Pickering I. J. (2004). Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury. *Chemical Research in Toxicology*, 17(8), 999-1006.

Ghosh, S. K., Chaudhuri, J., Gachhui, R., Mandal, A., & Ghosh, S. (2007). Effect of mercury and organomercurials on cellular glucose utilization: a study using resting mercury-resistant yeast cells. *Journal of Applied Microbiology*, 102(2), 375-383.

Hagele, T. J., Mazerik, J. N., Gregory, A., Kaufman, B., Magalang, U., Kuppasamy, M. L., Marsh, C. B., Kuppasamy, P., Parinandi, N. L. (2007). Mercury activates vascular endothelial cell phospholipase D through thiols and oxidative stress. *International Journal of Toxicology*, 26(1), 57-69.

Kanthasamy, A. G., Kitazawa, M., Kanthasamy, A., & Anantharam, V. (2005). Dieldrin-induced neurotoxicity: Relevance to Parkinson's disease pathogenesis. *Neurotoxicology*, 26(4), 701-719.

Kastenholz, B. (2007). New hope for the diagnosis and therapy of Alzheimer's disease. *Protein and Peptide Letters*, 14(4), 389-393.

Kaur, P., Aschner, M., & Syversen, T. (2006). Glutathione modulation influences methyl mercury induced neurotoxicity in primary cell cultures of neurons and astrocytes. *Neurotoxicology*, 27(4), 492-500.

Kirby, D. (2005). *Evidence of harm: Mercury in vaccines and the autism epidemic: A medical controversy*. New York: Saint Martin's Press.

Koch, M., & Trapp, R. (2006). Ethyl mercury poisoning during a protein A immunoabsorption treatment. *American Journal of Kidney Diseases* 47(2), Art. No. E31.

Kokayi, K., Altman, C. H., Calley, R. W., & Harrison, A. (2006, September-October). Findings of and treatment for high levels of mercury and lead toxicity in Ground Zero rescue and recovery workers and Lower Manhattan residents. *Explore — The Journal of Science and Healing*, 2(5), 400-407.

Leong, C. C., Syed, N. I., & Lorscheider, F. L. (2001). Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. *Neuroreport*, 12(4), 733-737.

Marn-Pernat, A., Buturovic-Ponikvar, J., Logar, M., Horvat, M., & Ponikvar, R. (2005). Increased ethyl mercury load in protein a immuno adsorption. *Therapeutic Apheresis and Dialysis*, 9(3), 254-257.

Muran, P. J. (2006). Mercury elimination with oral DMPS, DMSA, vitamin C, and glutathione: An observational clinical review. *Alternative Therapies in Health and Medicine*, 12(3), 70-75.

Mutter, J., Naumann, J., Schneider, R., & Walach, H. (2007). Mercury and Alzheimer's disease. *Fortschritte Der Neurologie Psychiatrie*, 75(9), 528-540.

Mutter, J., Naumann, J., Schneider, R., & Walach, H. (2007). Mercury and Alzheimer's disease. *Fortschritte Der Neurologie Psychiatrie*, 75(9), 528-540.

Mutter, J., Naumann, J., Schneider, R., Walach, H., & Haley, B. (2005). Mercury and autism: Accelerating evidence? *Neuroendocrinology Letters*, 26(5), 439-446.

Pearce, R. K. B., Owen, A., Daniel, S., Jenner, P., & Marsden, C. D. (1997). Iterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. *Journal of Neural Transmission*, 104(6-7), 661-677.

Razagui, I. B. A., & Haswell, S. J. (2001). Mercury and selenium concentrations in maternal and neonatal scalp hair — Relationship to amalgam-based dental treatment received during pregnancy *Biological Trace Element Research*, 81(1), 1-19.

Reagan, R. (1984). *Abortion and the conscience of the nation*. Nashville, TN: Thomas Nelson Publishers.

Rohyans, J., Walson, P. D., Wood G. A., & Macdonald, W. A. (1984). Mercury toxicity following merthiolate ear irrigations. *Journal of Pediatrics*, 104(2), 311-313.

Rybicki, B. A., Johnson, C. C., Uman, J., Gorell, J. M. (1993). Parkinson's disease mortality and the industrial use of heavy-metals in Michigan. *Movement Disorders*, 8(1), 87-89.

Sweet, L. I., Passino-Reader, D. R., Meier, P. G., & Omann G. A. (2006). Effects of polychlorinated biphenyls, hexachlorocyclohexanes, and mercury on human neutrophil apoptosis, actin cytoskeleton, and oxidative state. *Environmental Toxicology and Pharmacology*, 22(2), 179-188.

U. S. Environmental Protection Agency, (2000). Mercury compounds. Retrieved December 27, 2007, from <http://www.epa.gov/ttn/atw/hlthef/mercury.html>

University of Minnesota. (2007). Mercury risk assessment. Retrieved December 28, 2007, from <http://enhs.umn.edu/hazards/hazardssite/mercury/mercriskassess.html>

Uversky, V. N., Li, J., & Fink, A. L. (2001). Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein — A possible molecular link between Parkinson's disease and heavy metal exposure. *Journal of Biological Chemistry*, 276(47), 44284-44296.

Weiss, B., Clarkson, T. W., & Simon, W. (2002). Silent latency periods in methyl mercury poisoning and in neurodegenerative disease. *Environmental Health Perspectives*, 110(Suppl. 5), 851-854.

Wojcik, D. P., Godfrey, M. E., Christie, D., & Haley, B. E. (2006). Mercury toxicity presenting as chronic fatigue, memory impairment and depression: Diagnosis, treatment, susceptibility, and outcomes in a New Zealand general practice setting (1994-2006). *Neuroendocrinology Letters*, 27(4), 415-423.

World Health Organization. (2003). Elemental mercury and inorganic mercury compounds: Human health aspects. Retrieved December 28, 2007, from <http://www.who.int/ipcs/publications/cicad/en/cicad50.pdf>

World Health Organization. (n. d.). *Mercury in health care: Policy paper*. Retrieved December 28, 2007, from http://www.who.int/water_sanitation_health/medicalwaste/mercurypolpaper.pdf

Yokel, R. A. (2006). Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. *Journal of Alzheimer's Disease*, *10*(2-3), 223-253.

Yole, M., Wickstrom, M., & Blakley, B. (2007). Cell death and cytotoxic effects in YAC-1 lymphoma cells following exposure to various forms of mercury. *Toxicology*, *231*(1), 40-57.

Yole, M., Wickstrom, M., & Blakley, B. (2007). Cell death and cytotoxic effects in YAC-1 lymphoma cells following exposure to various forms of mercury. *Toxicology*, *231*(1), 40-57.

Zahir, F., Rizwi, S. J., Haq, S. K., Khan, R. H. (2005). Low dose mercury toxicity and human health. *Environmental Toxicology and Pharmacology*, *20* (2), 351-360.